{"id":"0a84f0bbbcbb","type":"article","url":"https://hartvaat.nl/2026/01/12/werkzaamheid-en-veiligheid-van-lage-doses-spironolacton-bij-primair-aldosteronis/","title":"Werkzaamheid en veiligheid van lage doses spironolacton bij primair aldosteronisme","title_en":"Efficacy and Safety of Treatment With Low Doses of Spironolactone in Patients With Primary Aldosteronism: A Retrospective Observational Study in a Tertiary Center","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","lorundrostat","mra-aldosteronantagonisten","spironolacton"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24881","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.24881","authors":["Elisa Sconfienza"],"significance":6,"published":"2026-01-12","source_date":"2026-01-12","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This retrospective study evaluated the efficacy and safety of low-dose spironolactone in primary aldosteronism, showing that reduced doses may achieve adequate blood pressure and potassium control with fewer side effects.","created":"2026-07-03T10:25:34Z","updated":"2026-07-03T13:24:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Spironolacton is eerstelijnstherapie bij idiopathisch primair aldosteronisme. Deze retrospectieve studie in een tertiair centrum evalueerde de impact van lage versus hoge doses op bloeddrukcontrole, kaliumwaarden en bijwerkingen.","abstract_original":"Hypertension, Volume 83, Issue 5, Page e24881, May 1, 2026. BACKGROUND:Spironolactone is recommended as first-line therapy for patients with idiopathic primary aldosteronism. The aim of this study is to evaluate the impact of low and high doses of spironolactone on arterial blood pressure control, potassium levels, and the incidence of drug-related adverse effects.METHODS:We retrospectively included 394 patients with primary aldosteronism receiving spironolactone. Patients were divided into 2 groups, according to the median prescribed dose in our population (50 mg, 25–75): subjects treated with doses ≤50 mg versus >50 mg.RESULTS:The median follow-up after the introduction of spironolactone was 12 months, and 128 patients experienced adverse effects, with a proportion higher in men than in women (44.70% versus 15.70%). The most frequently reported adverse effect was gynecomastia, followed by sexual dysfunction. Subjects receiving a dose >50 mg of spironolactone displayed a"}